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Abstract
Background: The current study was designed to determine if follitropin alfa (recombinant human
follicle-stimulating hormone; r-hFSH) and lutropin alfa (recombinant human luteinizing hormone; r-
hLH) biopotencies were unchanged by reconstituting in sterile water for injection and mixing prior
to injection.
Methods: The biopotencies of r-hFSH and r-hLH were determined following injection of female
Sprague-Dawley rats with a mixture of follitropin alfa revised formulation female (RFF) and lutropin
alfa (1:1, r-hFSH:r-hLH). Biopotencies of follitropin alfa RFF and lutropin alfa were measured using
ovarian weight and ascorbic acid depletion assays, respectively, and compared with a reference
standard. Stock mixtures of follitropin alfa RFF and lutropin alfa (1:1) were prepared within 1 h
prior to each respective assay's injection and stored at 6 +/- 2°C. Separate low dose (follitropin alfa
RFF 1.5 IU/rat, lutropin alfa 2 IU/rat) and high dose (follitropin alfa RFF 3 IU/rat, lutropin alfa 8 IU/
rat) treatments were prepared from stock mixtures or individual solutions by diluting with 0.22%
bovine serum albumin saline solution and injected within 1 h of preparation. The main outcome
measures were ovarian weight and ovarian ascorbic acid depletion.
Results: FSH bioactivities were similar (p > 0.10) between the individual follitropin alfa RFF test
solution (84.2 IU) and follitropin alfa RFF/lutropin alfa (87.6 IU) mixtures prepared within 1 h of
injection and stored at 6 +/- 2°C. LH bioactivities were similar (p > 0.10) between lutropin alfa (94.7
IU) test solution and lutropin alfa/follitropin alfa RFF (85.3 IU) mixtures prepared within 1 h of
injection and stored at 6 +/- 2°C for not more than 1 h prior to injection.
Conclusion: Mixing follitropin alfa RFF and lutropin alfa did not alter the bioactivity of either FSH
or LH.
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Background
In 1988, human follicle-stimulating hormone (hFSH)
was successfully expressed using Chinese hamster ovary
cells, representing the initial steps for commercial devel-
opment of gonadotropin products originating from
recombinant deoxyribonucleic acid (r-DNA) technology
[1]. The first recombinant hFSH, GONAL-f® (r-hFSH, foll-
itropin alfa for injection), was licensed in 1995 for mar-
keting in the European Union [2]. By the turn of the
century, recombinant human luteinizing hormone (r-
hLH, lutropin alfa for injection, Luveris®) and recom-
binant human chorionic gonadotropin (r-hCG, choriogo-
nadotropin alfa injection, Ovidrel®) were also
commercially produced, marking the availability of all
three human recombinant gonadotropins for infertility
treatment.
Until the successful introduction of the recombinant pro-
teins, gonadotropin products for the treatment of infertil-
ity consisted of a partially purified mixture of urine-
derived FSH, LH and/or chorionic gonadotropin (hCG).
While the urine-derived products have long represented
the mainstay of infertility therapy, the recombinant prod-
ucts alone provide the distinct advantage of solo adminis-
tration. That is, unlike the urine-based derivatives, r-hFSH
and r-hLH can be administered either independently or in
combination, in ratios that are static or vary during the
course of therapy. For the clinician, dosing flexibility of
the individual gonadotropins offers the potential to tailor
treatment according to the patient's distinct gonadotropin
requirements. The use of individualized protocols to stim-
ulate follicular development reflects concepts originally
elaborated by Brown (the FSH threshold) [3] and Hillier
(the LH ceiling) [4], and builds on scientific knowledge
regarding the continuum of follicular development
through an FSH-dependent phase and a period of LH-
responsive maturation [4,5]. In fact, numerous recent
clinical investigations have focused on controlled ovarian
stimulation (COS) protocols that incorporate LH activity
at various doses and phases in the treatment cycle [5-8].
The potential disadvantage of utilizing a combinative
approach, however, is that the recombinant gonadotropin
products are generally administered as separate injections.
The inconvenience of preparing for and administering
two injections may be considerable, depending on the
prescribed daily dose. Some healthcare providers have
instructed their patients on methods for mixing the prod-
ucts together, thereby obviating the need for a second
injection [9]. Clinical outcomes appeared to be unaffected
by this practice.
le Cotonnec and colleagues compared the potential inter-
actions of r-hLH with r-hFSH when administered individ-
ually or combined in one injection in a prospective,
randomized, Phase I, crossover study of 12 healthy, pitui-
tary down-regulated women [10]. Patients received single
doses of 150 IU r-hFSH plus 150 IU r-hLH, alone or com-
bined in a single syringe, followed by 150 IU r-hFSH plus
150 IU r-hLH, alone or combined in a single syringe once
daily for 7 days. No pharmacokinetic (PK) interactions
between the products were observed after single dosing or
in combination. Furthermore, no correlations were found
between maximum serum FSH or LH concentrations and
the pharmacodynamic (PD) responses recorded, includ-
ing serum estradiol and inhibin concentrations, and ovar-
ian follicular growth. The authors concluded that there
were no PK or PD differences between separate and com-
bined administration of r-hLH and r-hFSH.
In the current study, the objective was to determine if
lower doses (75 IU r-hFSH and 75 IU r-hLH) of individual
follitropin alfa revised formulation female (RFF) and
lutropin alfa biopotencies remained unchanged after mix-




Follitropin alfa RFF biopotency was determined using the
traditional Steelman-Pohley hCG augmentation assay,
which measures ovarian hypertrophy resulting from exog-
enous FSH treatments of immature female rats when
administered in conjunction with hCG [11]. According to
regulatory requirements, FSH biological activity of FSH-
containing gonadotropins is assessed by the same Steel-
man-Pohley bioassay used in this study [12-15]. Biopo-
tency of lutropin alfa was determined using the ovarian
ascorbic acid depletion assay, which measures the
decrease in ovarian ascorbic acid in response to exoge-
nous LH treatments administered to pseudo-pregnant rats
[16]. This assay was chosen due to its greater sensitivity for
detecting LH compared to the hyperemia, ventral prostate,
and interstitial cell assays. Moreover, the ovarian ascorbic
acid depletion assay is 8-, 33-, and 40-fold more sensitive,
respectively, than the aforementioned assays [16].
Although the Van Hell seminal vesicle weight gain bio-
assay is designated by regulatory authorities to determine
the LH biological activity of LH-containing gonadotropin
products, the ovarian ascorbic acid depletion assay was
used in this analysis for the reasons described [16,17].
Reference standards
The National Institute of Biological Standards and Con-
trols (NIBSC) Urinary Follicle Stimulating Hormone and
Urinary Luteinizing Hormone, 4th International Standard,
NIBSC Code: 98/704 (NIBSC, Herts, UK) reference stand-
ard was prepared for each replicate assay by dissolving a
single vial (FSH assay) or two vials (LH assay) each with
1.0 ml sterile saline solution and subsequently pooled, inReproductive Biology and Endocrinology 2008, 6:31 http://www.rbej.com/content/6/1/31
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the case of the latter. By definition of the World Health
Organization Expert Committee on Biological Standardi-
zation, the NIBSC 98/704 standard contains 72 IU of uri-
nary FSH and 70 IU of urinary LH per ampoule [18]. The
NIBSC 98/704 standard was used because a similar stand-
ard was not available for a combination of recombinant
FSH and recombinant LH.
Test animals
Twenty-two-day-old female Sprague-Dawley rats (Harlan,
Indianapolis, IN) were used for each bioassay (FSH assay,
n = 121; LH assay, n = 112). Each treatment group was
housed in individual cages, 30 × 40 cm, in a temperature-
controlled room (22 ± 2°C). Animals were given access to
water ad libitum, and fed a rat pellet consisting of 19%
crude protein, ≥ 5.0% crude fat, ≤ 5.0% crude fiber. The
supplier certified the animals to be free of common
viruses, bacteria, and parasites. All animal studies were
approved by the Institutional Animal Care and Use Com-
mittee.
Commercial products were supplied by EMD Serono, Inc.
(Rockland, MA, USA). Each 75 IU follitropin alfa RFF for
injection (GONAL-f® RFF) and 75 IU lutropin alfa for
injection (Luveris®) mono-dose vial was overfilled to
accommodate potential reconstitution and administra-
tion losses to insure delivery of the 75 IU dose [12,17]. As
determined by the respective Steelman-Pohley and Van
Hell bioassays, the release specifications for the commer-
cial product used was FSH = 75.5 IU/vial (GONAL-f® RFF
batch number 1970606D01) and LH = 94.2 IU/vial
(Luveris® batch number 5150911D) (data on file with
Merck Serono International S.A., Geneva, Switzerland).
Three 75 IU mono-dose vials of follitropin alfa RFF and
five 75 IU mono-dose vials of lutropin alfa were reconsti-
tuted with their accompanying diluent (1 ml Sterile Water
for Injection [SWFI]) for each assay. The reconstituted
products were pooled to provide sufficient stock material
for each replicate assay, e.g. 3 ml for follitropin alfa RFF
and 5 ml for lutropin alfa. Stock mixtures of follitropin
alfa RFF and lutropin alfa (1:1) were prepared within 1 h
prior to each respective assay's injection and stored at 6±
2°C. The 1:1 ratio of follitropin alfa RFF and lutropin alfa
used in the assay is consistent with the NIBSC 98/704
standard of urinary FSH and urinary LH used in this assay.
Preliminary FSH and LH assays were conducted to deter-
mine the optimum linear response dosages for the respec-
tive assays. Separate low dose (follitropin alfa RFF 1.5 IU/
rat, lutropin alfa 2 IU/rat) and high dose (follitropin alfa
RFF 3 IU/rat, lutropin alfa 8 IU/rat) treatments were pre-
pared from stock mixtures or individual solutions by
diluting with 0.22% bovine serum albumin saline solu-
tion and injected within 1 h of preparation. The FSH assay
was conducted in duplicate, utilizing 8 rats per dose per
replicate assay, totaling 16 rats per dose per assay. The LH
assay was conducted in triplicate, utilizing 5 rats per dose
per replicate assay, totaling 15 rats per dose per assay.
FSH bioassay
For the FSH bioassay, 121 23-day-old Sprague-Dawley
rats were injected with test solution, twice daily, for 3
days. Standard doses of test solutions (regardless of body
weight) were used for practicality. Respective high and
low doses were diluted in diluent containing hCG and
administered subcutaneously using a 1 cc syringe
equipped with a 1/2 inch × 25 1/2 gauge needle
(Monoject, Sherwood Medical, St. Louis, MO) in 0.5 ml
injection volumes at 8 am and 5 pm. The total hCG dose
was 20.5 IU/rat. Animals were euthanized 74 ± 2 h after
the initial injection, ovaries were removed and excised
free of fat and connective tissue, and promptly weighed
using a Sartorius scale (model BP 61, Sartorius Corp.,
Edgewood, NY) to the nearest 0.1 mg. Test solutions were
quantified against the reference standard.
FSH bioactivity was calculated according to the United
States Pharmacopeia (USP), utilizing ovarian weights
according to the following formula:
M' = cih'Ta/2ΣTb
where: M' = the log-relative potency of each unknown;
c = the constant taken from Table 6 in USP 28-NF [19];
i = the interval in logarithms between successive log-
doses;
h' = the number of values of Tb summed in the denomina-
tor;
Ta = Ti for the difference in the responses to the standard
and to the unknown;
Tb = Ti for the combined slope of the dosage response
curves for the standard and unknown [19].
Confidence intervals (CI) were calculated according to
USP 28-NF [19].
LH bioassay
For the LH bioassay, 112 26-day-old Sprague-Dawley rats
were pre-treated with 50 IU/rat pregnant mare serum
gonadotropin (PMSG). At 29 days of age, 62 ± 2 h after
PMSG treatment, hCG, 25 IU/rat, was injected to induce
pseudo-pregnancy. Nine days following hCG administra-
tion (aged 39 days), rats were weighed and treated with
test solutions intravenously (using 2.8 IU per 100 g body
weight). Rats were lightly anesthetized with ether, andReproductive Biology and Endocrinology 2008, 6:31 http://www.rbej.com/content/6/1/31
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drug was injected into the tail vein using a 1 cc syringe
(Monoject, Sherwood Medical) equipped with a 1/2 inch
× 25 1/2 gauge needle. The 2 and 8 IU doses were admin-
istered in a 0.5 ml solution per 100 g body weight.
Following a 4 h ± 10 min incubation period, rats were
euthanized, ovaries removed and promptly excised free of
fat and connective tissue, blotted on filter paper, and
weighed to the nearest 0.1 mg. Mean (SD) rat weight was
124.3 (7.1) g. Ovaries were immediately homogenized in
10.0 ml 2.5% metaphosphoric acid. Tissue homogenate
was assayed for ascorbic acid concentration using the Par-
low modification of Mindlin and Butler [20].
Test solutions were quantified against the reference stand-
ard. USP LH bioactivity was calculated using ascorbic acid
concentrations according to the same formula used for the
FSH bioactivity.
Statistical analysis
According to the USP, FSH or LH potency is adequate if it
falls within a range of 80–125% of the labeled potency
and if the confidence interval is not >1.8 [19]. When the
confidence limit from replicate assays was determined, it
was <0.18, and therefore no data was omitted from anal-
ysis because of exceeding the CIs. Data were analyzed
using ANOVA procedures to examine differences among
reference standard, individual gonadotropins, and the fol-
litropin alfa RFF/lutropin alfa mixture treatment groups.
Since no significant differences were found, treatment
means were not separated.
Results
FSH bioactivities (Table 1) of the individual follitropin
alfa RFF test solution and follitropin alfa RFF/lutropin alfa
(1:1) mixtures stored at 6 ± 2°C within 1 h prior to injec-
tion were similar (p > 0.10). The mean FSH IU for the FSH
standard was 72 IU/vial (range, 65.4–79.3).
LH bioactivities (Table 2) were not statistically different
between the individual lutropin alfa test solution and
lutropin alfa/follitropin alfa RFF (1:1) mixtures stored at
6 ± 2°C within 1 h prior to injection (p > 0.10). The mean
LH IU for the LH standard was 70 IU/vial (range, 58.2–
84.1). The results for the low and high dose mixtures were
factored into the formula above.
Discussion
For over 20 years, the mainstay of female infertility treat-
ment was human menopausal gonadotropins (hMG), an
injectable medication extracted from human urine with
FSH and LH activity. During the 1980–90s, a host of tech-
nological improvements led to greater purity of urinary
products and the availability of recombinant gonadotro-
pins. The recombinant products differed from hMG in
several significant ways: (1) purity, (2) mode of adminis-
tration, e.g. self-administered by subcutaneous injection
versus patient-assisted intramuscular injection, and (3)
the presence of a single, well-characterized gonadotropin
protein (r-hFSH, r-hLH, or r-hCG) [21]. The purity and
characterization of recombinant gonadotropins paved the
way for novel research on the roles of FSH and LH in fol-
licular development and facilitated the independent titra-
tion of FSH and LH for the benefit of infertile patients
[22].
Infertility treatment protocols are individualized accord-
ing to a variety of factors, including the patient's age and
diagnosis, ovarian reserve, history of prior response to
COS, and co-administered medications. Due to the com-
plexity of treatment, patients prefer the fewest number of
steps to prepare each injection [23]. Accordingly, the need
for administration of mixed doses of recombinant FSH
and LH is becoming more apparent.
The results of the current study demonstrated that the bio-
logical potency of a mixture of 75 IU of follitropin alfa
RFF (freeze-dried formulation) and 75 IU lutropin alfa in
a 1:1 ratio, after reconstitution in SWFI using a plastic
syringe, was similar to the biological potency of the indi-
vidual respective recombinant hormones when adminis-
tered within 1 h of injection and stored at 6 ± 2°C. As a
result, this study has shown that follitropin alfa RFF and
lutropin alfa may be mixed, without any significant alter-
ations in either the resulting FSH or LH bioactivity, if
administered within 1 h. It is important to note, however,
that the results of this study cannot be extrapolated to
other FSH or FSH-containing products, such as follitropin
beta injection (a recombinant-derived product), urofolli-
tropin for injection, purified or menotropins for injection,
USP (urine-derived products). The urine-derived products
are reconstituted with 2 ml 9% sodium chloride injection,
USP. Follitropin beta injection is a 0.5 ml vial containing
the active ingredient, excipients, and water for injection,
USP.
Table 1: Follicle-stimulating hormone (FSH) bioactivities (mean and 95% confidence interval)
Follitropin alfa RFF (n = 37) Follitropin alfa RFF/lutropin alfa mixture (1:1) (n = 32)
FSH bioactivity per vial (IU of NIBSC 98/704) 84.2 (75.5–92.7) 87.6 (79.1–96.5) p > 0.10
RFF, revised formulation female.Reproductive Biology and Endocrinology 2008, 6:31 http://www.rbej.com/content/6/1/31
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The inherent lack of precision is a widely recognized
shortcoming of the in vivo bioassays used to quantify
gonadotropin content prior to release of commercial
gonadotropin products [2,21]. The Steelman-Pohley in
vivo bioassay used to determine FSH content is highly spe-
cific but it lacks precision, as the coefficient of variation
(CV) in a single determination is 10–20% [24]. The USP,
the official authority that establishes standards for the
quality of all prescription products sold in the United
States, describes the methods used to identify gonadotro-
pin biopotency. The USP monograph specifies that these
products contain ≥ 80% and ≤ 125% of the hormones
listed on the products' labels [19]. As noted by Driebergen
and Baer, realistically, a 75 IU vial of FSH could contain
between 60 and 94 IU (80–125%) based on the bioassay,
and between 48 and 117 IU based on the same bioassay's
CV (10–20%) [24].
In the present study, the mean and 95% CI for follitropin
alfa RFF alone was 84.2 IU (75.5–92.7), while that of the
follitropin alfa RFF/lutropin alfa mixture was 87.6 IU
(79.1–96.5). These results are consistent with the assay
limitations previously discussed. Therefore, regardless of
the product source (urine- or recombinant-derived), the
FSH biopotency will vary because of the assay and not
necessarily the FSH product itself. Because a highly con-
sistent glycosylation profile is produced batch-to-batch,
follitropin alfa RFF may be assessed through physico-
chemical means [24].
The ovarian ascorbic acid depletion assay was used to
assess the biopotency of LH in the current study. Although
the Van Hell seminal vesicle weight gain bioassay is used
by regulatory authorities to assess the LH content of gona-
dotropin products, the ovarian ascorbic acid depletion
assay remains the most widely used in vivo bioassay for
quantifying LH [25]. The ovarian ascorbic acid depletion
assay is easy to perform and, furthermore, results correlate
better than those of the seminal vesicle weight assay with
in vitro LH assays [25,26]. However, the precision of the
ovarian ascorbic acid depletion assay is limited by hetero-
geneity in the structure of LH, endogenous interferences,
and inter-laboratory variability [25].
As previously described, le Cotonnec et al. evaluated the
PK and PD interactions between 150 IU follitropin alfa
and 150 IU lutropin alfa in a prospective, randomized
crossover study in 12 healthy women [10]. No statistically
significant differences were observed for tmax, Cmax, or
AUC between the single and combined doses for either r-
hLH or r-hFSH. PD markers that measured the response to
r-hFSH (serum estradiol and inhibin concentrations, and
follicular number and size) were not markedly affected by
r-hLH when both products were administered together.
However, the formulations of follitropin alfa and lutropin
alfa used by le Cotonnec et al. in this Phase I study differed
from those currently marketed in the USA; the current for-
mulations of both products include methionine and
polysorbate 20 [12,17].
Reassuringly, the results of this study show that currently
marketed formulations of follitropin alfa RFF and lutro-
pin alfa may be mixed without significant alterations in
the resulting bioactivity of either FSH or LH.
Conclusion
Mixing follitropin alfa RFF and lutropin alfa in plastic
syringes and administering the mixture within 1 h did not
alter the bioactivity of either FSH or LH.
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